XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Business Acquisitions (Narrative) (Details) - USD ($)
 12 Months Ended
Sep. 20, 2021
Jul. 20, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]          
Issuance of common stock in Private Placement, net of issuance costs       $ 294,845,000  
Acquisition-related costs       31,129,000  
Stock-based compensation expense     $ 78,613,000 80,728,000 $ 17,533,000
Goodwill     409,974,000 409,974,000  
Finite-Lived Intangible Assets, Gross   $ 11,400,000 11,539,000    
Income Tax Expense (Benefit)       (93,649,000)  
Circulomics, Inc [Member]          
Business Acquisition [Line Items]          
Total cash paid   29,500,000      
Goodwill   $ 19,309,000      
Omniome, Inc [Member]          
Business Acquisition [Line Items]          
Total cash paid $ 315,703,000        
Fair value of share consideration 249,435,000        
Fair value of contingent consideration 168,574,000        
Contingent Consideration Incurred during period $ 168,600,000        
Issuance of common stock 8,911,580        
Consideration $ 714,789,000        
Acquisition-related costs 12,000,000.0     12,000,000.0  
Stock-based compensation expense 18,900,000        
Income tax benefit from reduction in deferred tax assets valuation allowance 91,000,000.0        
Pro forma adjustment related to acquiree's acquisition-related costs 16,700,000        
Since the date of acquisition, revenues       0  
Since the date of acquisition, net loss       15,600,000  
Goodwill 390,665,000   410,000,000.0    
Omniome, Inc [Member] | Effect of Change Higher/(Lower) [Member]          
Business Acquisition [Line Items]          
Goodwill       (1,600,000)  
Deferred Tax Liabilities, Deferred Expense       (400,000)  
Income Tax Expense (Benefit)       $ (1,200,000)  
Omniome, Inc [Member] | Omniome stock awards related to acquisition [Member]          
Business Acquisition [Line Items]          
Total cash paid 7,400,000        
Fair value of share consideration 6,300,000        
Contingent Consideration Incurred during period $ 5,200,000        
Issuance of common stock 226,811        
Consideration $ 18,900,000        
Achievement of milestone [Member] | Omniome, Inc [Member]          
Business Acquisition [Line Items]          
Total cash paid 100,000,000        
Fair value of share consideration 100,000,000        
Fair value of contingent consideration 200,000,000        
Stock options issued by PacBio in replacement of Omniome’s unvested options $ 4,100,000        
Percentage of outstanding shares of common to be issued in merger 19.90%        
Issuance of common stock in Private Placement, net of issuance costs $ 11,500,000        
Developed Technology [Member]          
Business Acquisition [Line Items]          
Finite-Lived Intangible Assets, Gross     $ 11,179,000